|
AT9283 Trialed to Fight Leukemia
Cancer Research UK's Drug Development Office has opened the first trial of a new type of drug to treat children aged from six months to 18 years with acute leukemia, who are no longer responding to treatment.
...continue
Pfizer Sued Over Retirement Plans
Employees of Pfizer Inc. have filed suit against the company, alleging the world's largest drug maker failed to properly manage its retirement plans and caused losses totaling hundreds of millions over the past decade.
...continue
HPV Affects 7% of Americans
About 16 million Americans have oral HPV, a sexually transmitted virus more commonly linked with cervical cancer that also can cause mouth cancer, according to the first nationwide estimate.
...continue
Novartis Paying $99M Settlement
A U.S. division of Swiss drugmaker Novartis AG will pay $99 million to settle a class-action lawsuit about overtime pay for U.S. sales representatives.
...continue
BMS Profit Skyrockets
Bristol-Myers Squibb Co. reported a 76% increase in fourth-quarter profit, driven in part by sales of a recently approved diabetes drug and hefty charges a year earlier, though the drugmaker still fell short of Wall Street's expectations.
...continue
|
|
More Headlines
|
|
Ongoing Progress in Cancer Research
 The latest edition of Vital Signs presents research advances in understanding the mechanisms and origins of cancer, developments on treatments, preventions, and cures. The lead article, "Taking a Jab at Cancer", describes how cancer vaccine developers are overcoming scientific challenges and investor resistance.
...continue
The Search for CNS Cures
 Advances in medicine and healthcare are helping people live longer. However, healthcare systems and governments may not be prepared to deal with the medical, economic, and social challenges of an aging population.
...continue
Cancer Research Moves Forward
 While the last few decades have been witness to progress in cancer research, many challenges remain. This edition of Vital Signs reviews new research and new tools that may change the way cancer is diagnosed and treated.
...continue
|
|
More Vital Signs
|
|
 Genomics & Proteomics
Safety Through Sequencing
 Great strides have been made in identifying new drug targets and understanding mechanisms of disease. However, the science of drug safety lags behind, and rare toxic reactions torpedo otherwise promising drugs.
...continue
|
Policy & Projections
Trimming the Fat
 As lawmakers continue to grapple with the nation’s burgeoning federal budget deficit, healthcare spending has moved into the cross-hairs of fiscal and legislative debate.
...continue
|
Technology Advances
Creating Higher Content
 Whenever possible, drug researchers want one process to quickly reveal a collection of information. This makes high-content screening and analysis increasingly important in drug discovery.
...continue
|
|
DDD subscriptionFree Drug Discovery & Development
Industry Subscriptions
Magazine
 Newsletters
|
|
|
|
qPCR Primers for Intercalating Dyes
Integrated DNA Technologies’s genome-wide PrimeTime qPCR Primers are the same pairs used in the PrimeTime qPCR Assays, selected to detect and quantify gene expression in human, mouse, and rat transcriptomes.
...continue
Low-Volume Measurements
Thermo Fisher Scientific Inc.’s µDrop Plate for the measurement of samples down to 2 µL provides a way of analyzing 16 microliter-scale samples simultaneously.
...continue
Acoustically Compatible Microplates
Labcyte Inc. and Qiagen’s FlexiPlate siRNA reagent libraries are available in Labcyte Echo qualified microplates. The microplates use the Echo liquid handler to miniaturize the transfer of small interfering RNA reagents.
...continue
|
|
More
|
|
|
Researchers Discover Rotational Motion of Cells
Scientists with the U.S. Department of Energy’s Lawrence Berkeley National Laboratory have discovered a rotational motion in human breast cells that continues through mitosis and enables the cells and their progeny to form sphere-shaped acini.
...continue
Pharma Executives: CRO Partnerships Key to Speeding Drug Research
Pharmaceutical and biopharmaceutical companies, under pressure to increase R&D productivity, are expanding the use of strategic partnerships to bring new drugs to market more quickly and at lower cost, according to a panel of leaders from Tufts University.
...continue
Inherited Mutation Links Exploding Chromosomes to Cancer
 An inherited mutation in the guardian of the genome is likely the link between exploding chromosomes and some aggressive types of cancer, scientists at the European Molecular Biology Laboratory, the German Cancer Research Centre, and the University Hospital have discovered.
...continue
NPO Role Outlined in New White Paper
The Multiple Myeloma Research Foundation announced the publication of a white paper which explores how non-profit organizations are taking on a larger role and driving progress in drug development.
...continue
Therapy Dose Management During Clinical Development of Oncology Products
Body surface area (BSA) has long been the gold standard for determining the appropriate dose of chemotherapeutic agents. Numerous studies, however, have shown that this results in large patient variability due to variations in drug biodistribution, genetic variation, metabolism, and clearance.
...continue
|
|
More Recommended Reading
|
|
Updated Fall 2011 Edition:
When looking for the most promising leads, or compounds worth developing, drug researchers always seek new tools and techniques that enhance the odds of finding a marketable compound as soon as possible.
A wide variety of new oncology targets continue to be identified, many through investigations into the tumor microenvironment associated with solid tumors and tumor stem cell characteristics.
With the FDA cracking down on manufacturing irregularities, stricter provisions to the Physician Payment Sunshine Act being discussed, and Congress looking for a way out its budget troubles; the congeniality between regulators and the biopharmaceutical industry is slipping away.
For the first time, WPA users have the opportunity to control their spectrophotometer from a Windows PC. Resolution software is available in four different suites that enable users to meet individual application requirements.
The Tankyrase 1 Activity assay from AMSBIO is a screening kit for the identification of tankyrase 1 inhibitors in an in vitro system. These kits offer sensitivity down to 0.1 mUnits of tankyrase 1 and operate in a 96-well microplate format.
Durably constructed, the thick-walled Arctic Rack-24 from Micronic is a rack and cover enabling high integrity sample storage at cryogenic temperatures over extended periods of time.
